Education
About Us
Working with TipRanks
Follow Us
Orthocell Ltd (AU:OCC)
ASX:OCC
OCC Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.35 - AU$1.79
Previous CloseN/A
Volume2.26M
Average Volume (3M)855.85K
Market Cap
AU$306.61M
Enterprise ValueAU$44.77M
Total Cash (Recent Filing)AU$30.84M
Total Debt (Recent Filing)AU$657.93K
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Aug 28, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding243,344,090
10 Day Avg. Volume617,641
30 Day Avg. Volume855,847
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)11.23
Price to Sales (P/S)0.00
P/FCF Ratio4.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.32Price Target Upside4.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Orthocell Ltd News
PremiumCompany Announcements
Orthocell Expands Market Presence with New Share Issuance
PremiumCompany Announcements
Orthocell Ltd Announces Quotation of New Securities on ASX
PremiumCompany Announcements
Orthocell Expands Remplir™ Sales to Hong Kong with New Regulatory ApprovalPremiumCompany Announcements
Orthocell Expands US Distribution Network for Remplir™
PremiumCompany Announcements
Orthocell Gains Health Canada Approval for Nerve Repair Product Remplir
PremiumCompany Announcements
Orthocell Limited Requests Trading Halt for Pending Announcement
PremiumCompany Announcements
Orthocell Limited Initiates Trading Halt Ahead of Major Announcement
PremiumCompany Announcements
Orthocell Expands into Thai Market with Remplir™ ApprovalOptions Prices
Currently, No data available
---
Ownership Overview
3.20% Insiders
―
Mutual Funds
― Other Institutional Investors
96.72% Public Companies and
Individual Investors
OCC FAQ
What was Orthocell Ltd’s price range in the past 12 months?
Orthocell Ltd lowest share price was AU$0.35 and its highest was AU$1.79 in the past 12 months.
What is Orthocell Ltd’s market cap?
Orthocell Ltd’s market cap is AU$306.61M.
When is Orthocell Ltd’s upcoming earnings report date?
Orthocell Ltd’s upcoming earnings report date is Aug 28, 2025 which is in 75 days.
How were Orthocell Ltd’s earnings last quarter?
Orthocell Ltd released its earnings results on Feb 24, 2025. The company reported -AU$0.006 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.006.
Is Orthocell Ltd overvalued?
According to Wall Street analysts Orthocell Ltd’s price is currently Undervalued.
Does Orthocell Ltd pay dividends?
Orthocell Ltd does not currently pay dividends.
What is Orthocell Ltd’s EPS estimate?
Orthocell Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Orthocell Ltd have?
Orthocell Ltd has 243,344,090 shares outstanding.
What happened to Orthocell Ltd’s price movement after its last earnings report?
Orthocell Ltd reported an EPS of -AU$0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.383%.
Which hedge fund is a major shareholder of Orthocell Ltd?
Currently, no hedge funds are holding shares in AU:OCC
Orthocell Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.32 (4.76% Upside)
AU$1.32 (4.76% Upside)
Blogger Sentiment
Bullish
AU:OCC Sentiment 99%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth AU$100.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
240.54%
12-Months-Change
Fundamentals
Return on Equity
-29.77%
Trailing 12-Months
Asset Growth
60.70%
Trailing 12-Months
Company Description
Orthocell Ltd
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia. The company offers CelGro, a naturally derived collagen medical device for use in multiple indications to augment the surgical repair of bone, peripheral nerves, tendons, and cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation to treat articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membrane used for guided bone and tissue regeneration in dental application; and Remplir, a collagen scaffold used in peripheral nerve repair. Orthocell Limited was incorporated in 2006 and is headquartered in Murdoch, Australia.
Technical Analysis
Paradigm Biopharmaceuticals
―
Immutep Ltd
―
Dimerix Limited
―
Recce Pharmaceuticals Ltd.
―
Arovella Therapeutics Limited
―